Document is current
Any future updates will be listed below
-
Authors
Schagerholm Stanev, Caroline
Robertson, Stephanie
Toosi, Hosein
Sifakis, Emmanouil G.
Lagergren, Jens
Hartman, Johan
-
Funding
Funding for this research was provided by:
Region Stockholm
The Swedish Breast Cancer Association
MedTechLabs
The Cancer Society in Stockholm
The Swedish Cancer Society
The Swedish Society for Medical Research
- License Information
-
More Information
Article History
Received: 12 January 2026
Accepted: 18 August 2026
First Online: 30 August 2026
Declarations
Competing interests: The authors declare the following competing interests: J.H. has obtained speaker’s honoraria or advisory board remunerations from Roche, Novartis, AstraZeneca, Pfizer, Eli Lilly, MSD, Sakura, and Gilead, and has received institutional research support from Cepheid, Novartis, Roche, MSD, and AstraZeneca. J.H. is a co-founder and shareholder of Stratipath AB. E.G.S. serves as a scientific advisor to OnMune P.C. and holds stock options in the company. S.R. is employed by Stratipath AB and holds employee stock options and has received speaker’s honoraria from Novartis and Roche. C.S.S. has received speaker’s honoraria from Novartis and is employed by the Swedish Breast Cancer Association. All other authors declare no competing interests.
